SecBot SecBot
6-K ·Filed Aug 31, 2026

ASND

Ascendis Pharma A/S
NEUTRAL
Impact 6/10
Horizonweeks Processed2mo ago SEC0001193125-26-376733
Notable filing: 6-K
Actionable Insight • Neutral

The settlement removes a major IP overhang and enables full commercialization of YUVIWEL and other navepegritide products, a positive catalyst. However, the royalty burden is material (18-20% on net sales) and will pressure margins for several years. Traders should watch for a definitive agreement and first commercial sale timelines, which will determine when the royalty expense begins.

DirectionNeutral
Confidencehigh
Horizonweeks

YUVIWEL

◆ Mixed Named in this 6-K
Impact
Phase
Approved (FDA Accelerated Approval, February 2026)
Time to market
Already approved and commercially available in the US (launched April 2026). EMA approval in Europe is pending with no publicly confirmed date.
Next catalyst
None dated

What to watchThe binary approval catalyst has passed. Investors should now watch the commercial ramp (prescription trends, payer access, revenue contribution in upcoming quarterly reports) and any announcement of the confirmatory trial timeline or EMA filing date. The weekly-vs-daily dosing advantage is real, but first-mover BioMarin's Voxzogo ($927M in 2025 sales) is entrenched.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$260.25
T+0 close · Aug 31, 2026 · via day close
Latest settled
−12.46%
T+20 · $227.83 · next T+60 in 8d
Vs SPY
−12.77%
α at T+20
Latest observation
+6.90%
T+51 · FF3 residual α
  1. T+0 · Sep 1 $260.25entry
  2. T+1 · 3mo ago +2.71%α +2.27% · $267.31
  3. T+5 · 2mo ago +0.22%α +0.13% · $260.81
  4. T+20 · 7w ago −12.46%α −12.77% · $227.83
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma announced a binding term sheet for a global settlement and license agreement with BioMarin, resolving all litigation over YUVIWEL and navepegritide-related products. Ascendis will pay royalties of 20% in the US and 18% in the EU/South Korea/Brazil from first commercial sale of YUVIWEL through May 2030. The settlement provides critical IP certainty for Ascendis's pipeline but imposes a significant royalty burden on future sales.

Key Facts

  • Binding term sheet signed for global settlement and license agreement with BioMarin on August 31, 2026.
  • BioMarin grants non-exclusive, worldwide, royalty-bearing license for navepegritide-related products.
  • Ascendis to make royalty payments: 20% of net sales in the United States, 18% in the EU, South Korea, and Brazil.
  • Royalties run from first commercial sale of YUVIWEL in each country through May 20, 2030.
  • All litigation and disputes between the two companies will be dismissed.

Financial Impact

Unspecified, but royalties are 20% (US) and 18% (EU/South Korea/Brazil) of net sales on navepegritide-related products through May 2030.

revenueoperating margin

Risk Factors

  • Royalty payments (20% US, 18% ex-US) reduce unit economics on YUVIWEL and other navepegritide products.
  • Potential delays in final definitive agreement or commercial launch of YUVIWEL.
  • Competition or market acceptance challenges could limit revenue offsetting royalty drag.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-376733
Document: 0001193125-26-376733-index-headers.html0001193125-26-376733
Document: 0001193125-26-376733-index.html0001193125-26-376733
Document: 0001193125-26-376733.txt0001193125-26-376733

Track record

41 reports on ASND

Performance horizon

14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 25 of 27 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (11h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026